Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bifidobacterium bifidum CCFM1063 and application thereof

A technology of Bifidobacterium bifidum and functional bacterial agent, applied in the field of microorganisms, can solve the problems of increased risk of death of type 2 diabetes, and achieve the effects of relieving PFOA toxicity, relieving colitis, and improving the expression of MafA gene

Active Publication Date: 2019-10-15
JIANGNAN UNIV
View PDF3 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, studies have shown that workers exposed to PFOA have an increased risk of death from type 2 diabetes. Therefore, PFOA exposure in daily life is a potential risk of human type 2 diabetes.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bifidobacterium bifidum CCFM1063 and application thereof
  • Bifidobacterium bifidum CCFM1063 and application thereof
  • Bifidobacterium bifidum CCFM1063 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0090] Example 1: Bifidobacterium bifidum CCFM1063 has good tolerance to simulated gastrointestinal fluid

[0091] The cryopreserved Bifidobacterium bifidum CCFM1063 was inoculated in mMRS medium (MRS medium + 0.05% cysteine ​​hydrochloride), cultured anaerobically at 37°C for 48 hours, and then subcultured in mMRS medium for 2-2 hours. After 3 times, take 1 mL of the culture solution of Bifidobacterium bifidum CCFM1063, mix it with 9.0 mL of pH 2.5 artificial simulated gastric juice (containing 1% pepsin, mMRS medium at pH=2.5), and culture it anaerobically at 37°C. Samples were taken at 0h, 0.5h, 1h, and 2h, and the mMRS agar medium was used to pour culture to count plate colonies, determine the number of viable bacteria and calculate their survival rate.

[0092] The survival rate is the ratio of the logarithmic value of the number of viable bacteria at the time of sampling to the logarithmic value of the number of viable bacteria at the 0th hour in the culture solution, ex...

Embodiment 2

[0098] Example 2: Bifidobacterium bifidum CCFM1063 has no toxic side effects on C57BL / 6J mice

[0099]Bifidobacterium bifidum CCFM1063 cells were resuspended in 3% sucrose solution to make a concentration of 3.0×10 9 CFU / mL bacterial suspension. Eight healthy male C57BL / 6J mice with a body weight of about 16-20 g were taken. After one week of adaptation to the environment, the bacterial suspension of this concentration was administered orally once a day, observed for one week, and the death and body weight were recorded.

[0100] The results of these tests are listed in Table 3. These results indicate that feeding concentrations of 3.0×10 9 CFU / mL of Bifidobacterium bifidum CCFM1063 had no significant effect on mice, no significant change in body weight, and no death. The appearance of the mice had no obvious pathological symptoms.

[0101] Table 3 Changes in body weight and death of mice

[0102]

[0103] Note: -: no death of mice

Embodiment 3

[0104] Example 3: Bifidobacterium bifidum CCFM1063 has a recovery effect on intestinal flora imbalance in type 2 diabetic mice

[0105] Take 40 healthy male C57BL / 6J mice weighing 16-20g, adapt to the environment for 1 week, and divide them into 5 groups randomly: blank control group (NC), model control group (M), rosiglitazone control group (RH) , Bifidobacterium bifidum CCFM1063 intervention group (CCFM1063), Bifidobacterium bifidum BB12 control group (BB12) each group contains 8 mice, and the dosage of gavage bacterial suspension is 3.0×10 9 CFU / mL, resuspended in 3% sucrose solution. The grouping and treatment methods of experimental animals are shown in Table 4:

[0106] Table 4 Grouping of experimental animals

[0107]

[0108]

[0109] Week 2-7: The mice in the normal group were fed with normal feed, and the rest of the mice were fed with high-fat feed.

[0110] On the 1st day of the 11th week, all mice were fasted for 12 hours, the normal group was injected wi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to View More

Abstract

The invention discloses bifidobacterium bifidum CCFM1063 and application thereof. The bifidobacterium bifidum CCFM1063 can be rapidly planted in an intestinal tract, fasting blood-glucose and oral glucose tolerance caused by type II diabetes is significantly improved, and the area under the curve for glucose tolerance is reduced; total cholesterol in a serum increased and high-density lipoproteincholesterol reduced caused by the type II diabetes are significantly improved; the condition of insulin resistance caused by the significantly improved is significantly improved; the level of inflammation in type II diabetes liver tissue is significantly improved; pathological injuries of tissue such as pancreas and liver caused by the type II diabetes are significantly improved; the bifidobacterium bifidum CCFM1063 has higher adsorption capacity on perfluoro caprylic acid, and has the capacity of relieving toxicity of the perfluoro caprylic acid; and the constipation condition caused by the type II diabetes is significantly improved and the level of Allobaculum genus in the intestinal tract is improved, and functions of relieving anxiety and depression and colonitis are achieved.

Description

technical field [0001] The invention belongs to the technical field of microorganisms, and in particular relates to Bifidobacterium bifidum CCFM1063 and application thereof. Background technique [0002] In recent years, the development of the economy has led to changes in the lifestyle of the Chinese people, a decrease in activity, a significant increase in the proportion of obesity, and a substantial increase in the prevalence of diabetes and metabolic syndrome (Metabolic Syndrome). According to the International Diabetes Federation (IDF), in 2017, 425 million people over the age of 19 suffered from diabetes worldwide. If this trend continues, the number of diabetic patients will reach 693 million in about 30 years. Therefore, controlling diabetes has become an urgent matter. [0003] Because type 2 diabetes is a pathological state in which a variety of metabolic components are abnormally aggregated, and its clustering is related to insulin resistance, it has become a com...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N1/20A23L33/135A61K35/745A61P1/00A61P1/10A61P1/16A61P1/18A61P3/10A61P25/22A61P25/24C12R1/01
CPCC12N1/20A23L33/135A61K35/745A61P1/00A61P1/10A61P1/16A61P1/18A61P3/10A61P25/22A61P25/24A23V2002/00C12R2001/01C12N1/205A23V2200/328A23V2200/3262A23V2200/32A23V2200/31A23V2400/517
Inventor 王刚陈卫司倩赵建新张灏
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com